Royal Philips
- Market cap
- 23.55B
- P/E (TTM)i
- 18.72
- P/Bi
- 1.84
- EPSi
- 1.04
- Div yieldi
- 4.12%
- 52W posi
- 5%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Royal Philips (PHG) | 23.55B | 18.72 | 1.84 | 4.12% |
| Abbott Laboratories (ABT) | 170.84B | 31.95 | 3.34 | 2.47% |
| Medtronic (MDT) | 109.38B | 21.06 | 2.18 | 3.33% |
| Stryker Corp (SYK) | 105.64B | 28.54 | 4.40 | 1.26% |
| Boston Scientific (BSX) | 60.26B | 16.83 | 2.42 | 0.00% |
| Edwards Lifesciences (EW) | 49.44B | 49.87 | 4.66 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 33.0% below Morningstar's fair value estimate.
Fair value
Koninklijke Philips NV receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 24% discount to our quantitative fair value estimate of $32.04 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The company's valuation metrics strengthen our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.3 ranks in the top 40% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be cheap.
The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 7.7%, a core component of profitability, ranks in the top 30% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.
Economic moat
The company's excess returns on capital and superb profitability, which could persist for decades or more, warrant a wide economic moat rating. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-10-08 07:42:34 · For reference only, not investment advice and not tailored to your situation.